Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 165   

Articles published

NVS 82.87 -0.64 (-0.77%)
price chart
Can Novartis AG (ADR) Reach Financial Stability via Restructuring?
As Novartis AG (ADR) (NYSE:NVS) head of pharmaceuticals, David Epstein, announced his departure from the company, it initiated the process of restructuring the business portfolios.
Novartis AG Enbrel Biosimilar Receives FDA Approval
The US Food and Drug Administration (FDA) Advisory Committee has approved Novartis AG's (ADR) (NYSE:NVS) GP2015, a biosimilar version of Enbrel.
Novartis AG (ADR) First-Quarter Earnings: What to Expect?
Novartis AG (ADR) (NYSE:NVS) is set to announce its financial results for the first quarter of 2016 (1Q) on Thursday, April 21.
Novartis AG (ADR) (NYSE:NVS) Stops Phase III Trial of Arzerra for Pemphigus ...
Seven months after acquiring the autoimmune indications rights to Arzerra from GlaxoSmithKline plc (ADR) (NYSE:GSK), Novartis AG (ADR) (NYSE:NVS) has ended the Phase III trial of Genmab A/S' (CPH:GEN) drug on those suffering from pemphigus ...
Novartis AG (ADR) Aiming to Target Biosimilar Market by 2020
By 2020, Novartis AG (NYSE:NVS) plans to launch a number of biosimilar versions of the blockbuster drugs in order to enter multiple therapeutic markets.
Two European stocks in Focus: Novartis AG (ADR) (NVS), AstraZeneca plc (ADR) (AZN)
Novartis AG (ADR) (NVS) develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz.
Amgen, Inc. (NASDAQ:AMGN) Has Sued Novartis' AG (ADR) (NYSE:NVS) Sandoz Unit ...
Top-selling anti-inflammatory drug Enbrel from Amgen, Inc. (NASDAQ:AMGN) is facing steep competition from biosimilars that are hitting the market at a very rapid speed.
Amgen Inc to Face Off Pfizer & Novartis to Save Key Drugs  Bidness ETC
Ls Investment Advisors LLC Decreased Stake in Novartis Ag Spon Adr (NYSE:NVS ...
Ls Investment Advisors Llc decreased its stake in Novartis Ag Spon Adr (NYSE:NVS) by 97.91% based on its latest 2016Q1 regulatory filing with the SEC.
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Pfizer Inc, Sanofi SA (ADR), Novartis AG (ADR): Who Will Acquire Medivation Inc?
As the merger and acquisition (M&A) spree is booming, multiple pharmaceutical companies have put Medivation Inc. (NASDAQ:MDVN) on the top of their acquisition list.